Full-Time
Develops precision radiation therapy equipment and software
$125k - $135k/yr
Senior
Company Does Not Provide H1B Sponsorship
Georgia, USA
Hybrid work option (you are required to work on location at least 3 days/week)
Upload your resume to see how it matches 7 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Elekta focuses on precision radiation medicine, providing advanced technologies for treating cancer and brain disorders. The company develops and distributes radiation therapy equipment and software solutions that help clinicians improve patient outcomes and streamline their workflows. Elekta generates revenue through the sale of these medical devices and related services, catering to hospitals, cancer treatment centers, and healthcare providers. A key aspect of Elekta's mission is to expand access to radiation therapy, especially in underserved areas. The company also prioritizes sustainability and aims to increase its global presence by growing its installed base of machines.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Stockholms kommun, Sweden
Founded
1972
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Paid Vacation
Hybrid Work Options
Wellness Program
Tuition Reimbursement
Mary Bird Perkins has partnered with Elekta for years, introducing many leading-edge technologies to ensure that patients have access to the best cancer care possible.
Elekta has announcement the appointment of Jonas Bolander as Acting President and Chief Executive Officer (CEO).
May 14, 2024 - Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high-definition AI enhanced imaging, capable of delivering offline and online adaptive radiation therapy as well as improved standard image-guided radiation therapy treatments.
Complementing the launch of Evo, Elekta has introduced a new extension to its comprehensive software suite, Elekta ONE Planning, powered by MIM.
STOCKHOLM – Elekta (EKTA-B.ST) announces the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent portfolio. This strategic move bolsters Elekta’s position in treatment planning and underscores its commitment to being the innovation leader in radiation therapy.Elekta and Philips have reached an agreement to transfer Philips’ patent portfolio in the radiation oncology treatment planning domain to Elekta, unlocking further innovations in radiation therapy treatment planning and workflow optimization. By integrating the technologies covered by the acquired patent portfolio, Elekta and Philips aim to offer a seamless and best-in-class transition for existing Pinnacle users to Elekta ONE Planning, including data conversion services, showcased at the upcoming ESTRO event.In June 2021, Elekta and Philips announced their long-term strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions, from CT and MR simulation to treatment planning, preparation and delivery.Maurits Wolleswinkel, President, Linac and Software Solutions at Elekta, said: “Thanks to continued investments over the years, our treatment planning system supports both Elekta and non-Elekta devices, including proton therapy, making Elekta ONE Planning one of the most competitive solutions in the market. At ESTRO, we will unveil exciting new capabilities, including novel scripting elements inspired by Pinnacle, demonstrating Elekta ONE’s competitive advantage.”Martijn Hartjes, Business Leader Clinical Informatics at Philips, added: “We are pleased that we can continue to support our customers with leading solutions in radiation oncology. This is a logical next step in the strong long-term collaboration between Philips and Elekta in the radiotherapy domain to improve cancer care together.”See a live demo of Elekta ONE, and how it will elegantly include Pinnacle-related technology, at ESTRO 2024, May 3-7 in Glasgow, UK at Elekta’s booth #440.# # #For further information, please contact:Mattias Thorsson, Vice President, Head of Corporate CommunicationsTel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.comTime zone: CET: Central European TimeRaven Canzeri, Global Director, Media RelationsTel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.comTime zone: ET: Eastern TimeAbout ElektaAs a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer